|
|
 |
|
Viewing report
|
|
|
|
Neuropathic Pain Market Forecast
Datamonitor, Jan 2011
Introduction
At present, only six drugs are indicated for the treatment of neuropathic pain. In 2010, two significant events impacted the neuropathic pain market: the launch of Qutenza (8% capsaicin patch; NeurogesX/Astellas) in the US and EU; and the high-profile failure of ralfinamide (NW-1029; Newron) for the treatment of neuropathic low back pain.
Features and benefits
- In depth analysis of historic (2005–09) and future (2010–19) seven major market prescription sales dynamics.
- Includes neuropathic pain and country-specific sales forecasts for key brands, generics and pipeline drugs in the seven major markets to 2019.
Highlights
- The neuropathic pain market is expected to achieve peak sales of $4.1bn over the forecast period (2010–19) across the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK).
- In addition to existing brands expanding into new regions, Datamonitor forecasts a total of eight pipeline candidates to enter the neuropathic pain market over the forecast period (2010–19) across the seven major markets.
- The broad label approval of Nucynta ER (extended-release tapentadol; Johnson & Johnson/Grünenthal) will drive market growth, while the launch of novel and topical agents will broaden treatment options.
Your key questions answered
- What will be the impact of major generic launches to the neuropathic pain market and what are the implications to prospective players?
- What are the most promising drug candidates in development for the potential treatment of neuropathic pain?
- What is the expected uptake of topical reformulations for neuropathic pain?
- What is the commercial potential of Qutenza (8% capsaicin patch; NeurogesX/Astellas) following its 2010 launch?
Customers who bought this item also bought
Pipeline and Commercial Insight: Neuropathic Pain - Pipeline setbacks prolong Pfizer's supremacy
The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights
The Pain Market Outlook to 2016
Neuropathic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2018
The Top 50 Developers Of Pain Management Pharmaceuticals Worldwide
Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta
Key Companies: Neuropathic Pain - In-house to in-license as Big Pharma cuts down on early-stage research
Pain Therapeutics - Drugs, Markets and Companies
Neuropathic Pain: Emerging Drugs and Current Treatment Practices
US Cancer Pain Report
|
|
|
|
